Title

ALL-071: A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Affiliations

Advocate Lutheran General Hospital

Presentation Notes

Poster presented at: SOHO 2021; September 8-11, 2021; Virtual.

Document Type

Abstract

Link to Full Text

 

Share

COinS